Clinical Edge Journal Scan

PsA: Swapping biologics gives no remarkable advantage over cycling


 

Key clinical point: In a real-life cohort of patients with psoriatic arthritis (PsA), using drugs with the same (cycling) mode of action (MoA) after the failure of the previous one was not remarkably better than using the drug with a different MoA (swapping) than the previously failed drug.

Major finding: Drug retention rate was not significantly different between the group that underwent swapping vs. cycling (hazard ratio [HR] 0.95; 95% confidence interval [CI], 0.52-1.74), and effectiveness of swapping was not different from that observed in the first-line prescription group (HR, 1.45; 95% CI, 0.83-2.52).

Study details: This was a monocentric medical records review study of 183 patients with PsA treated with biologic disease-modifying antirheumatic drugs (DMARDs) or targeted synthetic DMARDs. The medical records were grouped into cycling, swapping, or first-line groups.

Disclosures: The authors did not identify any source of funding. The authors declared no conflicts of interest.

Source: Ariani A et al. Medicine (Baltimore). 2021 Apr 23. doi: 10.1097/MD.0000000000025300 .

Recommended Reading

Clinical Edge Journal Scan: PsA May 2021
MDedge Rheumatology
Multiple studies highlight pandemic’s impact on patients with rheumatic disease
MDedge Rheumatology
Trial: Fecal transplantation safe but ineffective in PsA
MDedge Rheumatology
Lower SARS-CoV-2 vaccine responses seen in patients with immune-mediated inflammatory diseases
MDedge Rheumatology
Clinical Edge Journal Scan Commentary: PsA June 2021
MDedge Rheumatology
Is fecal microbiota transplantation beneficial in active peripheral PsA?
MDedge Rheumatology
PsA: Guselkumab well tolerated with no new safety signals
MDedge Rheumatology
Secukinumab, a comprehensive biologic treatment for management of concomitant PsA and psoriasis
MDedge Rheumatology
PsA: No substantial change in body composition with ustekinumab treatment
MDedge Rheumatology
PsA: Upadacitinib shows consistent efficacy and safety in patients with inadequate response to biologics
MDedge Rheumatology